SPOTLIGHT: Booming vaccine biz boosts Sanofi income

Sanofi-Aventis says that the booming vaccine market will boost its income from the sector to 15 percent of its annual revenue in coming years, up from 10 percent. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.